IGC Pharma, Inc. (IGC): Financials
Trailing 12 months ended June 30, 2026
Income statement, cash flow and balance sheet figures for IGC Pharma, Inc. (IGC), read directly from the XBRL data the company files with the SEC. Over the trailing twelve months the company reported $1.1M of revenue, down 15.4% year over year. Net loss was $7.9M, or $-0.08 per diluted share. Free cash flow was -$5.9M. Gross margin stood at 21.9%.
Against the current share price, IGC trades at 26.0 times trailing revenue.
15 fiscal years of history are available, back to 2011.
Frequently asked questions
How much revenue does IGC make?
IGC Pharma, Inc. reported $1.1M of revenue over the trailing twelve months, for the period ended June 30, 2026. That is down 15.4% from the same period a year earlier.
Is IGC profitable?
IGC Pharma, Inc. was unprofitable over the trailing twelve months, with a net loss of $7.9M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.